NewEdge Advisors LLC Increases Holdings in Gilead Sciences, Inc. $GILD

Key Points

• NewEdge Advisors LLC increased its stake in Gilead Sciences by 3.2% during the first quarter, holding 94,586 shares worth approximately $10.6 million.
• Gilead Sciences recently reported $2.01 earnings per share for the last quarter, surpassing analysts' expectations and showing a slight year-on-year revenue growth of 1.4%.
• Several analysts have upgraded their ratings for Gilead Sciences, with target prices as high as $133.00, indicating positive sentiment in the market.

NewEdge Advisors LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.2% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 94,586 shares of the biopharmaceutical company's stock after acquiring an additional 2,933 shares during the quarter. NewEdge Advisors LLC's holdings in Gilead Sciences were worth $10,598,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the business. Redwood Financial Network Corp grew its position in Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after acquiring an additional 98 shares during the last quarter. Argentarii LLC grew its position in Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after acquiring an additional 99 shares during the last quarter. Peak Financial Advisors LLC grew its position in Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock valued at $677,000 after acquiring an additional 100 shares during the last quarter. Perkins Coie Trust Co grew its position in Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after acquiring an additional 100 shares during the last quarter. Finally, Investment Research & Advisory Group Inc. grew its position in Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 100 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Down 1.3%

GILD stock traded down $1.50 during trading on Friday, reaching $116.36. 1,633,794 shares of the company traded hands, compared to its average volume of 8,081,841. Gilead Sciences, Inc. has a 12 month low of $81.57 and a 12 month high of $121.83. The business has a 50 day simple moving average of $113.97 and a 200 day simple moving average of $110.07. The company has a market capitalization of $144.38 billion, a price-to-earnings ratio of 23.18, a price-to-earnings-growth ratio of 0.78 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same period last year, the business posted $2.01 earnings per share. The firm's revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $296,325.00. Following the completion of the sale, the chief financial officer owned 160,110 shares of the company's stock, valued at approximately $18,977,838.30. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 82,000 shares of company stock valued at $9,371,330. 0.27% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on GILD. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. UBS Group increased their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Royal Bank Of Canada increased their price target on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Finally, Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $115.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.